Getinge B stock edges higher on stable medtech valuation

Getinge B stock (ISIN SE0000202624) is quoted at 17.97 euros as of September 6, 2026 on a European trading venue, reflecting a modest gain of 0.09 euros or 0.48 percent compared with the previous close according to market data compiled by boerse.de. The same overview also places the share in the medtech sector with a C rating, a signal that investors are dealing with a mature but not high-growth name.

Valuation metrics for Getinge B

From a fundamental perspective, the latest available full-year figures for fiscal year 2024 show that Getinge B generated revenue equivalent to 34,759.00 units in its reporting currency, with a pre tax result of 2,282.00 and a net profit of 1,638.00 according to the boerse.de fundamentals table. In the same fiscal year 2024, earnings per share came in at 6.01 units while the book value per share stood at 121.18 units, highlighting that the share price implies a clear premium to the accounting equity.

Based on these 2024 figures, the valuation ratios used by boerse.de indicate a price earnings ratio of 30.45, a price book ratio of 1.51 and a price sales ratio of 1.43 for Getinge B. For investors, the comparison between the earnings per share of 6.01 units and the share price of 17.97 euros as of September 6, 2026 suggests that the current market quotation is far below the fiscal year 2024 earnings level, underscoring that the valuation is being driven by other factors such as currency conversion, sector positioning and expected profitability shifts.

Balance sheet and profitability context

The same 2024 data set shows total assets of 63,918.00 units, with equity of 33,005.00 units and total liabilities of 30,707.00 units, resulting in an equity ratio of 51.64 percent and a debt ratio of 48.36 percent according to boerse.de. On the profitability side, boerse.de reports a margin on sales of 4.71 percent and a return on equity of 4.96 percent for fiscal year 2024, metrics that place Getinge B firmly in the category of established but not high margin medtech providers.

Boerse.de also lists a workforce of 11,791 employees at year end 2024, with revenue per employee of 2,947,926.00 units and profit per employee of 138,920.00 units. For retail investors, the combination of a mid single digit return on equity and a substantial employee base underscores that Getinge B is operating as a global medtech group with stable but moderate profitability.

Representative product and medtech positioning

Getinge B is part of the wider Getinge group, which focuses on medical technology for intensive care, operating rooms and sterile supply, and is frequently present at international congresses such as ESICM LIVES 2026, a leading event for intensive care medicine highlighted on Getinge channels as of September 6, 2026. Participation in such events underscores the companys commitment to showcasing solutions for critical care and infection control, which are core revenue drivers in its hospital focused portfolio.

Getinge B stock and current market view

With Getinge B stock trading at 17.97 euros as of September 6, 2026 and showing a daily change of 0.09 euros or 0.48 percent according to boerse.de, the share price remains anchored in a valuation context that includes a fiscal year 2024 equity ratio of 51.64 percent and a return on equity of 4.96 percent, numbers that help investors gauge the balance between financial stability and profitability.